Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes

@inproceedings{Jang2011CandidateDP,
  title={Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes},
  author={Yun-Mi Jang and Dong-lim Kim},
  booktitle={Diabetes & metabolism journal},
  year={2011}
}
Corresponding author: Dong-Lim Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, 4-12 Hwayang-dong, Gwangjin-gu, Seoul 143-729, Korea E-mail: 20030057@kuh.ac.kr Type 2 diabetes mellitus (T2DM) is a progressive disease that is characterized by insulin resistance and decreased insulin secretion [1]. Based on data from the UK Prospective Diabetes Study (UKPDS), there is consensus regarding the importance of glycemic control in… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Effect of the dipeptidyl peptidase - 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes

B Charbonnel, A Karasik, J Liu, M Wu, G Meininger
  • 2006

Similar Papers

Loading similar papers…